This clinical trial for patients with ALK+ lung cancer seeks to understand and innovate future treatments.

The SPACEWALK trial (Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance) studies how ALK-positive lung cancer changes, starts growing again, and/or comes back after treatment with an ALK targeted therapy.  The trial is led by Dr. Geoffrey Oxnard of Dana Farber Cancer Institute who is the Chair of GO2 Foundation’s Scientific Leadership Board.

Patients whose cancer is growing after ALK targeted therapy [Alecensa (alectinib), Alunbrig (brigatinib), Zykadia (ceritinib), or Lorbrena (lorlatinib)] have their blood drawn and sent for analysis of biomarker changes.  The results are used to understand ALK biology and are also sent to the oncologist and patient to help inform treatment decisions.

Patients in any location in the United States, seeing any oncologist, can participate in the study.

 

For more information or to learn how to participate in the study, visit:

https://alcmi.net/research/spacewalk-study/

or call 844-44-SPACE (844-447-7223).